Airway Inflammatory Pathways Regulating Glucocorticoid Receptor Phosphorylation
气道炎症途径调节糖皮质激素受体磷酸化
基本信息
- 批准号:10159949
- 负责人:
- 金额:$ 9.27万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-12-01 至 2022-03-25
- 项目状态:已结题
- 来源:
- 关键词:AKT inhibitionAddressAffectAgeAntibodiesAsthmaBinding ProteinsBiopsyCell modelCellsDataDefectDevelopmentGenderGene ExpressionGenesGenetic TranscriptionGlucocorticoid ReceptorGlucocorticoidsGoalsGrowthGrowth FactorHumanImmuneImmunohistochemistryImpairmentIn VitroInflammatoryInsulinInsulin-Like Growth-Factor Binding Protein 1KnowledgeLaboratoriesLesionMAPK11 geneMediatingMissionMitogen-Activated Protein KinasesMolecularMorbidity - disease rateMutateNCOR1 geneNRIP1 geneNuclear TranslocationPathogenesisPathway interactionsPatientsPharmaceutical PreparationsPharmacologyPhosphoric Monoester HydrolasesPhosphorylationPhosphotransferasesPhosphotyrosinePlayProcessProtein Serine/Threonine PhosphataseProtein phosphataseProtein-Serine-Threonine KinasesProto-Oncogene Proteins c-aktReceptor SignalingResearchResearch PersonnelRoleSerineSignaling MoleculeSiteSmall Interfering RNASmooth Muscle MyocytesSpecificitySteroidsTestingTherapeuticTissuesTransactivationUnited States National Institutes of HealthUp-Regulationairway remodelingburden of illnessclinically significantcofactordesignexpression vectorfunctional disabilitygenetic corepressorin vivoinhibitor/antagonistinjured airwaymortalitymuscle formnew therapeutic targetnovel therapeuticsp38 Mitogen Activated Protein Kinasepreventpromoterpublic health relevancereceptor functionrecruitrespiratory smooth muscleresponsetooltranslational approach
项目摘要
PROJECT SUMMARY
Increased airway smooth muscle (ASM) mass, a major feature of airway remodeling in asthma,
profoundly contributes to asthma morbidity, mortality, and pathogenesis. This increased mass is due in
large part to enhanced proliferative activity of ASM cells. Unfortunately, proliferation of these latter cells is
unaffected by current asthma medications, as the process appears to be insensitive to glucocorticoid (GC)
effects. While research aimed at understanding the basis of GC insensitivity (GCI) has focused on the role of
immune cells, few investigators have studied GCI in ASM cells, the pivotal cell regulating bronchomotor tone.
The long-term goal of this research is to identify factors that impair the sensitivity of the ASM proliferative
response to GC in patients with asthma, with the ultimately goal of establishing therapeutic strategies to
circumvent GCI. The current proposal will examine the cellular and molecular mechanisms by which growth
factors (GFs) modulate ASM sensitivity to GCs. Using unique cellular models of ASM cells derived from patients
with asthma, our exciting preliminary data supports the central hypothesis that GF-induced abnormal site-specific
phosphorylation of glucocorticoid receptor (GR) impairs ASM sensitivity to GC. These data now suggest that
(previously unappreciated) GR phosphorylation at serine 134 (ser134) residue inhibits GR signaling. These data
also suggest that GF-induced activation of serine/threonine kinase protein kinase B (PKB/Akt) and
serine/threonine protein phosphatase 2A (PP2A) regulates GR-ser134 phosphorylation. The rationale for the
proposed research is that understanding the interplay among GR signaling and GF-induced kinases and/or
phosphatases may uncover critical information for the development of novel therapeutics to overcome GCI in
asthma. Our hypotheses will be tested by pursuing four specific aims: to identify the functional consequences of
GF-induced abnormal GR site-specific phosphorylation on GR signaling (Aim 1); to characterize the contribution
of kinases and phosphatases to GF-induced abnormal GR site-specific phosphorylation (Aim 2); and to elucidate
the role of steroid-target genes in modulating GC anti-proliferative effects in ASM cells (Aim 3). To this end, we
generated tools (antibody, mutated constructs) to examine the role of GR-ser134 phosphorylation. In all aims,
pharmacological inhibitors, mutated constructs, siRNA, and expression vectors will be used to modulate the
expression of steroid co-repressor, kinases, phosphatases, and steroid-target genes, after which GR site-specific
phosphorylation, GR-mediated transactivation activities and sub-cellular localization, and ASM growth will be
analyzed using state-of-the-art approaches already established in our laboratories. We will also determine the
clinical significance of our in vitro observations by examining whether the aforementioned pathways are activated
in tissues using endobronchial biopsies from subjects both with and without asthma (Aim 4). This integrated
translational approach is expected to advance our understanding of the mechanisms that contribute to the
development of GCI in some patients with asthma.
项目摘要
气道平滑肌(ASM)质量增加是哮喘气道重塑的主要特征,
哮喘发病率、死亡率和发病机制的重要因素。这种增加的质量是由于
很大程度上是由于ASM细胞的增殖活性增强。不幸的是,这些后一种细胞的增殖是
不受当前哮喘药物的影响,因为该过程似乎对糖皮质激素(GC)不敏感
方面的影响.虽然旨在了解GC不敏感性(GCI)基础的研究集中在以下方面的作用:
免疫细胞,很少有研究者研究GCI在ASM细胞,调节支气管张力的关键细胞。
本研究的长期目标是确定损害ASM增殖敏感性的因素,
哮喘患者对GC的反应,最终目标是建立治疗策略,
绕过GCI目前的建议将研究细胞和分子机制,
GFs调节ASM对GCs的敏感性。使用源自患者的ASM细胞的独特细胞模型
对于哮喘,我们令人兴奋的初步数据支持了中心假设,即GF诱导的异常位点特异性
糖皮质激素受体(GR)的磷酸化损害ASM对GC的敏感性。这些数据表明,
(以前未被认识到的)GR丝氨酸134(ser 134)残基磷酸化抑制GR信号传导。这些数据
还表明GF诱导的丝氨酸/苏氨酸激酶蛋白激酶B(PKB/Akt)的活化和
丝氨酸/苏氨酸蛋白磷酸酶2A(PP 2A)调节GR-丝氨酸134磷酸化。的理由
建议的研究是,了解GR信号传导和GF诱导的激酶和/或
磷酸酶可能揭示新疗法的发展,以克服GCI的关键信息,
哮喘我们的假设将通过追求四个具体目标进行测试:确定
GF诱导的GR位点特异性异常磷酸化对GR信号传导的影响(目的1);
激酶和磷酸酶对GF诱导的异常GR位点特异性磷酸化的影响(目的2);并阐明
类固醇靶基因在调节ASM细胞中GC抗增殖作用中的作用(Aim 3)。为此我们
产生的工具(抗体,突变的构建体),以检查GR-ser 134磷酸化的作用。在所有目标中,
药理学抑制剂、突变的构建体、siRNA和表达载体将用于调节
类固醇辅阻遏物、激酶、磷酸酶和类固醇靶基因的表达,之后GR位点特异性
磷酸化,GR介导的反式激活活性和亚细胞定位,以及ASM的生长将是
使用我们实验室已经建立的最先进的方法进行分析。我们还将确定
通过检查上述通路是否被激活,我们在体外观察的临床意义
使用支气管内活组织检查从患有和不患有哮喘的受试者的组织中(目的4)。这一综合
翻译的方法,预计将促进我们的机制,有助于了解
在某些哮喘患者中发生GCI。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
OMAR TLIBA其他文献
OMAR TLIBA的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('OMAR TLIBA', 18)}}的其他基金
TRUSS as a novel regulator of inflammatory genes in asthma
TRUSS 作为哮喘炎症基因的新型调节剂
- 批准号:
8897989 - 财政年份:2014
- 资助金额:
$ 9.27万 - 项目类别:
TRUSS as a novel regulator of inflammatory genes in asthma
TRUSS 作为哮喘炎症基因的新型调节剂
- 批准号:
8702540 - 财政年份:2014
- 资助金额:
$ 9.27万 - 项目类别:
Airway Inflammatory Pathways Regulating Glucocorticoid Receptor Phosphorylation
气道炎症途径调节糖皮质激素受体磷酸化
- 批准号:
8427314 - 财政年份:2012
- 资助金额:
$ 9.27万 - 项目类别:
Airway Inflammatory Pathways Regulating Glucocorticoid Receptor Phosphorylation
气道炎症途径调节糖皮质激素受体磷酸化
- 批准号:
9424454 - 财政年份:2012
- 资助金额:
$ 9.27万 - 项目类别:
Airway Inflammatory Pathways Regulating Glucocorticoid Receptor Phosphorylation
气道炎症途径调节糖皮质激素受体磷酸化
- 批准号:
10622111 - 财政年份:2012
- 资助金额:
$ 9.27万 - 项目类别:
Airway Inflammatory Pathways Regulating Glucocorticoid Receptor Phosphorylation
气道炎症途径调节糖皮质激素受体磷酸化
- 批准号:
8220499 - 财政年份:2012
- 资助金额:
$ 9.27万 - 项目类别:
Airway Inflammatory Pathways Regulating Glucocorticoid Receptor Phosphorylation
气道炎症途径调节糖皮质激素受体磷酸化
- 批准号:
8625331 - 财政年份:2012
- 资助金额:
$ 9.27万 - 项目类别:
Mechanisms of Steroid Resistance in Airway Smooth Muscle Cells
气道平滑肌细胞类固醇抵抗机制
- 批准号:
7753874 - 财政年份:2007
- 资助金额:
$ 9.27万 - 项目类别:
Mechanism of inflammation-induced steroid resistance
炎症诱导类固醇抵抗的机制
- 批准号:
7486327 - 财政年份:2007
- 资助金额:
$ 9.27万 - 项目类别:
Mechanisms of Steroid Resistance in Airway Smooth Muscle Cells
气道平滑肌细胞类固醇抵抗机制
- 批准号:
7684321 - 财政年份:2007
- 资助金额:
$ 9.27万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 9.27万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 9.27万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 9.27万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 9.27万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 9.27万 - 项目类别:
Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 9.27万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 9.27万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 9.27万 - 项目类别:
EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 9.27万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 9.27万 - 项目类别:
Research Grant